瑞舒伐他汀、阿托伐他汀在冠状动脉粥样硬化性心脏病调脂治疗中的药物经济学研究

Pharmacoeconomic study of Rosuvastatin and Atorvastatin in lipid-lowering therapy for coronary artery atherosclerotic heart disease

目的探讨瑞舒伐他汀、阿托伐他汀在冠状动脉粥样硬化性心脏病(以下简称“冠心病”)患者调脂治疗中的药物经济学。方法选取2020年7月至2021年7月吉林市人民医院收治的84例行调脂治疗的冠心病患者作为研究对象,采用随机数字表法分为观察组和对照组,每组42例。在基础治疗的基础上观察组采用瑞舒伐他汀进行调脂治疗,对照组则采用阿托伐他汀进行调脂治疗。两组均治疗8周,测定两组患者的低密度脂蛋白胆固醇(LDL-C),比较两组患者的调脂效果,并采用成本-效果分析法对瑞舒伐他汀、阿托伐他汀两种药物的经济学进行评价。结果两组治疗前的LDL-C水平比较,差异无统计学意义(P>0.05);两组治疗后的LDL-C水平均低于本组治疗前,差异有统计学意义(P<0.05);两组治疗后的LDL-C水平比较,差异无统计学意义(P>0.05)。两组调脂的总有效率比较,差异无统计学意义(P>0.05)。两组的不良反应总发生率比较,差异无统计学意义(P>0.05)。瑞舒伐他汀、阿托伐他汀治疗的成本-效果比分别为3.58元/%、4.03元/%,瑞舒伐他汀的增量成本-效果比为-4.30元/%。敏感性分析与该结果相符。结论在冠心病患者调脂治疗中,相较阿托伐他汀而言,瑞舒伐他汀的经济性更好。

Objective To explore the pharmacoeconomics of Rosuvastatin and Atorvastatin in lipid-lowering therapy for patients with coronary artery atherosclerotic heart disease(hereinafter referred to as"coronary heart disease").Methods A total of 84 patients with coronary heart disease treated with lipid-lowering therapy admitted to Jilin People's Hospital from July 2020 to July 2021 were selected as the research subjects.They were randomly divided into an observation group and a control group according to random number table method,with 42 patients in each group.On the basis of basic treatment,the observation group was treated with Rosuvastatin,and the control group was treated with Atorvastatin.after 8 weeks of treatment,low density lipoprotein cholesterol(LDL-C)were measured in both groups,and the lipid regulating effect were compared between the two groups.The cost-effectiveness analysis was used to evaluate the economics of Rosuvastatin and Atorvastatin.Results The LDL-C levels of the two groups before treatment were compared,there were no statistical significance(P>0.05);The LDL-C levels of both groups after treatment were lower than before treatment,the differences were statistically significant(P<0.05).The LDL-C levels between the two groups after treatment were compared,there were no statistical significance(P>0.05).The total effective rates between two groups of lipid regulation were compared,there were no statistical significance(P>0.05);The total incidence of adverse reactions between the two groups were compared,there were no statistical significance(P>0.05).The cost-effectiveness ratio of Rosuvastatin and Atorvastatin was 3.58 yuan/%and 4.03 yuan/%respectively,the incremental cost-effectiveness ratio of Rosuvastatin was-4.30 yuan/%.Sensitivity analysis was consistent with this result.Conclusion In lipid-lowering therapy for patients with coronary heart disease,Rosuvastatin has better cost-effectiveness compared to Atorvastatin.